A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

This study tests a combination of two drugs—elranatamab (an antibody that helps the immune system attack multiple myeloma cells) and cyclophosphamide (a chemotherapy drug)—for patients with multiple myeloma, a blood cancer of the bone marrow, who have already received prior treatments but have certain high-risk features. **You may be eligible if...** - You are 18 or older and have a confirmed diagnosis of multiple myeloma - Your cancer has measurable disease detectable in blood or urine tests - You have at least one high-risk feature (such as cancer spread outside the bone marrow, high beta-2 microglobulin levels, or high bone marrow involvement) - You have been treated previously with at least one drug from each of three major classes: an IMiD, a proteasome inhibitor, and an anti-CD38 antibody - Your blood counts and organ function meet minimum requirements **You may NOT be eligible if...** - You have previously received a bispecific antibody therapy for multiple myeloma - You have active CNS involvement, active serious infection (HIV, active hepatitis B or C, active COVID-19), or have had an organ transplant - You have had a recent serious heart event (heart attack, heart failure, blood clot) - You have a history of Guillain-Barré syndrome or severe nerve damage Talk to your doctor to see if this trial is right for you.